This final rule implements requirements of the Administrative Simplification subtitle of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), and the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, enacted on March 30, 2010--collectively, the Affordable Care Act. Specifically, this final rule adopts standards for health care claims attachments transactions, which will support health care claims transactions,

Original title: “Administrative Simplification; Adoption of Standards for Health Care Claims Attachments Transactions and Electronic Signatures”

The Food and Drug Administration (FDA or we) is announcing a delay of the effective date of our February 6, 2026, final order to amend the color additive regulations to provide for the expanded safe use of spirulina (Arthrospira platensis) extract as a color additive in human foods generally (except for infant formula, certain foods subject to regulation by the U.S. Department of Agriculture (USDA), and foods for which standards of identity have been issued under section 401 of the Federal Food,

Original title: “Listing of Color Additive Exempt From Certification; Spirulina Extract; Delay of Effective Date”

This Request for Information (RFI) is intended to gather broad public input to assist the National Institutes of Health (NIH) in developing the NIH-Wide Strategic Plan for Fiscal Years 2027-2031 (FY27-FY31). NIH invites input from stakeholders throughout the scientific research, advocacy, and clinical practice communities, as well as the general public, regarding the proposed framework for the FY27-FY31 NIH-Wide Strategic Plan. Organizations are strongly encouraged to submit a single response th

Original title: “Request for Information (RFI): Inviting Comments and Suggestions on a Framework for the NIH-Wide Strategic Plan for Fiscal Years 2027-2031”

The Food and Drug Administration (FDA or we) is announcing a delay of the effective date of our February 6, 2026, final order to amend the color additive regulations to provide for the safe use of beetroot red for the coloring of human foods generally, at levels consistent with current good manufacturing practice, except in products under the jurisdiction of the United States Department of Agriculture (USDA), infant formula, or foods for which standards of identity have been issued under section

Original title: “Listing of Color Additive Exempt From Certification; Beetroot Red; Delay of Effective Date”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled CDC's Milestone Tracker App User Surveys. CDC will collect voluntary, anonymous data

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled DELTA Cooperative Agreement Evaluation. This project is designed to collect data for

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

Original title: “Agency Forms Undergoing Paperwork Reduction Act Review”

In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership on the Mine Safety and Health Research Advisory Committee (MSHRAC). The MSHRAC consists of 10 experts in fields associated with mining safety and health research and practice.

Original title: “Solicitation of Nominations for Appointment to the Mine Safety and Health Research Advisory Committee”

Original title: “Office of the Director, Notice of Charter Renewal”

In compliance with the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

Original title: “Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)”

Referred to the House Committee on Agriculture.

Original title: “HR 3991: Research for Healthy Soils Act”

Motion to reconsider laid on the table Agreed to without objection.

Original title: “HRES 723: Providing for consideration of the bill (H.R. 4365) making appropriations for the Department of Defense for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4367) making appropriations for the Department of Homeland Security for the fiscal year ending September 30, 2024, and for other purposes; providing for consideration of the bill (H.R. 4665) making appropriations for the Department of State, foreign operations, and related programs for the fiscal year ending September 30, 2024, and for other purposes; and providing for consideration of the bill (H.R. 4368) making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2024, and for other purposes.”

Motion to reconsider laid on the table Agreed to without objection.

Original title: “HR 4368: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024”

The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking carbidopa/levodopa drugs. Both AbbVie and Novartis market levodopa-based products.

Original title: “FDA Warns of Seizure Risk With Some Parkinson’s Drugs”